Pharmacyclics' (PCYC) Phase II trial of its ibrutinib drug in patients with mantle cell...
Monday, August 20, 2012, 8:40 AM ETPharmacyclics' (PCYC) Phase II trial of its ibrutinib drug in patients with mantle cell lymphoma, a rare type of non-Hodgkin's lymphoma, enrolls its 5th patient, thereby triggering a second milestone payment of $50M from J&J (JNJ) unit Janssen Biotech. Additional $50M payments could be triggered up to a total of $250M. (First payment)
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles